Expression of Anti-apoptotic Protein BAG3 in Human Sebaceous Gland Carcinoma of the Eyelid

Yunoki, Tatsuya; Tabuchi, Yoshiaki; Hayashi, Atsushi

doi:10.21873/anticanres.11532

Cited by 10 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been reported that BAG3 is highly expressed in many kinds of primary tumors, including ovarian cancer, and glioblastoma [ 10 – 13 ]. In addition, BAG3 is able to modulate some tumor biology processes, involving cell apoptosis, growth, cytoskeleton organization, and differentiation [ 14 , 15 ]. Some studies have reported that the overexpression of BAG3 inhibits drug-induced or serum-deprivation apoptosis in some degree and the inhibition of BAG3 promotes tumor cell apoptosis.…”

Section: Introductionmentioning

confidence: 99%

Silencing of BAG3 inhibits the epithelial-mesenchymal transition in human cervical cancer

Song

Wang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Bcl2-associated athanogene 3 (BAG3) has been reported to be involved in aggressive progression of many tumors. In the present study, we examined the expression of BAG3 in human cervical cancer (CC) tissues and investigated the role of BAG3 in SiHa and HeLa cell growth, migration, and invasion. Here, we found that most of CC tissues highly expressed the protein and mRNA of BAG3, while their expression was obviously lower in paired normal tissues (all p<0.001). BAG3 expression was associated with FIGO stage and metastasis (all p<0.05). In-vitro analysis demonstrated that BAG3 siRNAs inhibited SiHa and HeLa cell growth, invasion and migration. Mechanically, BAG3 siRNAs inhibited the expression of EMT-regulating markers, involving MMP2, Slug and N-cadherin, and increased the expression of E-cadherin. In a xenograft nude model, BAG3 siRNAs inhibited tumor growth and the expression of EMT biomarkers. In conclusion, BAG3 is involved in the EMT process, including cell growth, invasion and migration in the development of CC. Thus, BAG3 target might be recommended as a novel therapeutic approach.

show abstract

Section: Introductionmentioning

confidence: 99%

Silencing of BAG3 inhibits the epithelial-mesenchymal transition in human cervical cancer

Song

Wang

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…BAG3 has been found to be upregulated during malignant cell transformation and is present in detectable amounts in pancreatic adenocarcinoma (PDAC), breast, lung, colorectal, ovarian and cervical cancers. Expression of BAG3 significantly effects the prognosis of cancer patients by hyper-activating cell-survival pathways, evading cell-death mechanisms and hindering the efficacy of commercially available chemotherapy and radiotherapy options (Basile et al, 2019;Chiappetta et al, 2012Chiappetta et al, , 2014Yunoki et al, 2017). This voracious nature of BAG3 is attributed to its multifaceted structure that allows it to play pivotal roles in cell pathways encompassing proliferation, metastasis, angiogenesis, autophagy, apoptosis and more.…”

Section: Procancerous Role Of Bag3mentioning

confidence: 99%

Corelating the molecular structure of BAG3 to its oncogenic role

Pattoo,

Khanday

2024

Cell Biology International

View full text Add to dashboard Cite

BAG3 is a multifaceted protein characterised by having WW domain, PXXP motif and BAG domain. This protein gets upregulated during malignant transformation of cells and has been associated with poorer survival of patients. Procancerous activity of BAG domain of BAG3 is well documented. BAG domain interacts with ATPase domain of Hsp‐70 preventing protein delivery to proteasome. This impediment results in enhanced cell survival, proliferation, resistance to apoptosis and chemoresistance. Besides BAG domain other two domains/motifs of BAG3 are under research vigilance to explore its further oncogenic role. This review summarises the role of different structural determinants of BAG3 in elevating oncogenesis. Based on the already existing findings, more interacting partners of BAG3 are anticipated. The anticipated partners of BAG3 can shed a wealth of information into the mechanistic insights of its proproliferative role. Proper insights into the mechanistic details adopted by BAG3 to curtail/elaborate activity of anticipated interacting partners can serve as a potent target for development of therapeutic interventions.

show abstract

“…The molecular mechanisms underlying the pathogenesis and progression of SGC remain to be fully elucidated. As is the case with other cancers, most SGC have point mutations in the p53 tumor suppressor gene ( 15 ) and overexpressed anti-apoptotic proteins including X-linked inhibitor of apoptosis (XIAP) ( 16 ) and BAG cochaperone 3 (BAG3) ( 17 ). High expression of growth factor receptors such as vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and platelet-derived growth factor receptor are also known as clinicopathologic features of SGC ( 18 ).…”

Section: Introductionmentioning

confidence: 99%

Bioinformatics analysis of the microRNA-mRNA network in sebaceous gland carcinoma of the eyelid

et al. 2020

View full text Add to dashboard Cite

Expression of Anti-apoptotic Protein BAG3 in Human Sebaceous Gland Carcinoma of the Eyelid

Abstract: Abstract.

Cited by 10 publications

References 24 publications

Silencing of BAG3 inhibits the epithelial-mesenchymal transition in human cervical cancer

Silencing of BAG3 inhibits the epithelial-mesenchymal transition in human cervical cancer

Corelating the molecular structure of BAG3 to its oncogenic role

Bioinformatics analysis of the microRNA-mRNA network in sebaceous gland carcinoma of the eyelid

Contact Info

Product

Resources

About